Clinical Trials Browser

Phase 1/2 × Non-Small Cell Lung Cancer With EGFR Mutation × osimertinib × Clear all

NCT06306456 2024-07-08

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Phase 1/2 Recruiting

Non-Small Cell Lung Cancer With EGFR Mutation